CANbridge Pharmaceuticals Inc. (01228) reported an unchanged authorized share capital of USD 50,000 as of January 31, 2026. The total issued shares rose from 511,120,234 to 511,222,234, reflecting an increase of 102,000 shares primarily due to share option exercises under the company's Post-IPO Share Option Scheme. The exercise of options generated HKD 227,960 during the period. The company confirmed continued compliance with public float requirements mandated by the Hong Kong Stock Exchange.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.